As recently as March 9, CureDuchenne was helping NS Pharma get the word out about their newly launched Expanded Access Program for enabling access to viltolarsen, a treatment for patients with DMD amenable to exon 53 skipping, while the FDA reviews the therapy. How much has changed in two short weeks! But NS Pharma and their viltolarsen study has remained on track.
Today, NS Pharma is letting us all know that to date, they have not experienced any disruptions to their ongoing studies of viltolarsen, their Expanded Access Program (EAP) or FDA’s review of viltolarsen’s New Drug Application (NDA). The Phase 3 RACER53 trial and the associated EAP are still enrolling. NS Pharma’s President, Tsugio Tanaka, says “The DMD community is always in our thoughts, more so now than ever, as we all take steps to protect ourselves, families, friends and neighbors during this unprecedented public health emergency.”
Email DMDresearch@nspharma.com with your questions and concerns.